Over 30,000 bottles of prescribed medications recalled nationwide: FDA

Nationwide recalls are underway for thousands of bottles and cartons of cholesterol medication, impacting patients across the United States. Both Zydus Pharmaceuticals (USA) Inc. and AvKARE have voluntarily initiated these recalls due to concerns regarding product quality.

Quality Concerns Prompt Medication Recalls

According to the U.S. Food and Drug Administration (FDA), Zydus is recalling 22,896 bottles of Icosapent Ethyl capsules, 1 gram, packaged in 120-count bottles. This recall, initiated on December 30, 2025, stems from subpotency issues caused by leakage and subsequent oxidation. This could lead to inconsistent therapeutic effects and a potential increase in gastrointestinal side effects for patients.

The affected lot numbers for the Zydus recall are S2520304, S2520333, and S2540186, all with expiration dates in 2027. Separately, AvKARE is recalling Rosuvastatin Tablets, USP, 10 mg, found in 50-tablet unit dose cartons. This recall, also initiated on December 31, 2025, is due to the product failing to meet specifications for dissolution.

The lot number impacted by the AvKARE recall is 49124, with an expiration date of December 31, 2026. Both recalls are currently ongoing, as per the FDA.

Did You Know? The Zydus recall involves products with expiration dates as late as 2027, indicating a potentially extended period of time during which affected medications were distributed.

Expert Insight: Recalls related to drug subpotency or dissolution issues highlight the critical importance of maintaining strict quality control standards in pharmaceutical manufacturing and distribution. Inconsistent medication strength or absorption can have significant implications for patient health outcomes.

Patients currently taking either Icosapent Ethyl capsules or Rosuvastatin Tablets from the affected lot numbers should consult with their healthcare provider. A possible next step for patients is to discuss alternative treatment options or obtain a new prescription from a different lot. It is likely that healthcare providers will advise patients not to discontinue medication without professional guidance.

Frequently Asked Questions

What is causing the Zydus recall?

The Zydus recall was initiated due to subpotency caused by oxidation from leakage, which may lead to inconsistent therapeutic effects and increased gastrointestinal side effects.

What is the reason for the AvKARE recall?

The AvKARE recall is due to the product being out of specification for dissolution.

Are these recalls still in progress?

Yes, both recalls are ongoing, according to the FDA.

How will these recalls impact individuals relying on these medications for managing their cholesterol levels?